Regenesis

Regenesis operates as a commercial-stage medical device company, not a cell therapy biotech as initially suggested. It has pivoted to commercializing the Reprieve electromagnetic diathermy system, a home-use device for chronic pain, with a significant focus on serving US military veterans. The company has established a direct sales model, reported historical revenue growth, and has clinical evidence for conditions like diabetic peripheral neuropathy and plantar fasciitis. Its core technology, originally conceived for cell proliferation induction, is now applied as a physical stimulus device for pain relief and tissue healing.

Electromagnetic shortwave diathermy for cell proliferation induction and deep tissue heating, delivered via a patient-operated home-use medical device.

Regenesis competes in the non-invasive physical medicine market against manufacturers of TENS units, therapeutic ultrasound devices, laser therapy, and other diathermy machines. Its key differentiation is FDA clearance for specific conditions, a focus on home-use, and a dedicated support model, particularly within the VA system.